fenofibrate and Chagas Disease studies

fenofibrate and Chagas Disease

fenofibrate has been researched along with Chagas Disease in 4 studies

Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE

Chagas Disease: Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.

Research Excerpts

Excerpt	Relevance	Reference
"Fenofibrate treatment restored to normal values the ejection and shortening fractions, left ventricular end-diastolic, left ventricular end-systolic diameter, and isovolumic relaxation time."	5.46	Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. ( Cevey, ÁC; Donato, M; Gelpi, RJ; Goren, NB; Mirkin, GA; Penas, FN; Rada, MJ, 2017)
"Fenofibrate treatment restored to normal values the ejection and shortening fractions, left ventricular end-diastolic, left ventricular end-systolic diameter, and isovolumic relaxation time."	1.46	Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. ( Cevey, ÁC; Donato, M; Gelpi, RJ; Goren, NB; Mirkin, GA; Penas, FN; Rada, MJ, 2017)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	3 (75.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

1 (25.00)

24.3611

2020's

3 (75.00)

2.80

Authors	Studies
Pieralisi, AV	2
Cevey, ÁC	3
Penas, FN	6
Prado, N	1
Mori, A	1
Gili, M	1
Mirkin, GA	3
Gagliardi, J	1
Goren, NB	6
Rigazio, CS	3
Mariz-Ponte, N	3
Pérez Caballero, E	3
Santamaría, MH	3
Corral, RS	3
Donato, M	2
Rada, J	1
Gelpi, RJ	2
Rada, MJ	1

Authors

Studies

Pieralisi, AV

Cevey, ÁC

Penas, FN

Prado, N

Mori, A

Gili, M

Mirkin, GA

Gagliardi, J

Goren, NB

Rigazio, CS

Mariz-Ponte, N

Pérez Caballero, E

Santamaría, MH

Corral, RS

Donato, M

Rada, J

Gelpi, RJ

Rada, MJ

Article	Year
Fenofibrate Increases the Population of Non-Classical Monocytes in Asymptomatic Chagas Disease Patients and Modulates Inflammatory Cytokines in PBMC. Frontiers in cellular and infection microbiology, 2021, Volume: 11 Topics: Animals; Chagas Disease; Cytokines; Fenofibrate; Humans; Leukocytes, Mononuclear; Mice; Monocytes	2021
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells. Microbial pathogenesis, 2022, Volume: 173, Issue:Pt A Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M	2022
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells. Microbial pathogenesis, 2022, Volume: 173, Issue:Pt A Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M	2022
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells. Microbial pathogenesis, 2022, Volume: 173, Issue:Pt A Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M	2022
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells. Microbial pathogenesis, 2022, Volume: 173, Issue:Pt A Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M	2022
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells. Microbial pathogenesis, 2022, Volume: 173, Issue:Pt A Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M	2022
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells. Microbial pathogenesis, 2022, Volume: 173, Issue:Pt A Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M	2022
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells. Microbial pathogenesis, 2022, Volume: 173, Issue:Pt A Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M	2022
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells. Microbial pathogenesis, 2022, Volume: 173, Issue:Pt A Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M	2022
The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells. Microbial pathogenesis, 2022, Volume: 173, Issue:Pt A Topics: Chagas Disease; Cyclooxygenase 2; Endothelial Cells; Fenofibrate; Humans; Inflammation; Macrophage M	2022
Macrophages Mediate Healing Properties of Fenofibrate in Experimental Chagasic Cardiomyopathy. ACS infectious diseases, 2023, 02-10, Volume: 9, Issue:2 Topics: Cardiomyopathies; Chagas Cardiomyopathy; Chagas Disease; Fenofibrate; Humans; Macrophages	2023
Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease. International journal for parasitology. Drugs and drug resistance, 2017, Volume: 7, Issue:3 Topics: Animals; Chagas Cardiomyopathy; Chagas Disease; Diastole; Fenofibrate; Fibrosis; Humans; Inflammatio	2017

Article

Year

Fenofibrate Increases the Population of Non-Classical Monocytes in Asymptomatic Chagas Disease Patients and Modulates Inflammatory Cytokines in PBMC.

Frontiers in cellular and infection microbiology, 2021, Volume: 11

Topics: Animals; Chagas Disease; Cytokines; Fenofibrate; Humans; Leukocytes, Mononuclear; Mice; Monocytes

2021

The combined action of glycoinositolphospholipid from Trypanosoma cruzi and macrophage migration inhibitory factor increases proinflammatory mediator production by cardiomyocytes and vascular endothelial cells.